A study of price-related pay across the supply chain is due in two years
What the document says“Not later than 2 years after the date of enactment of this section, the Comptroller General shall submit to Congress a report containing the results of the study conducted under paragraph (1), together with recommendations for such legislation and administrative action as the Comptroller General determines appropriate.”
Subsection (b) of section 6224 requires the Comptroller General to study compensation and payment structures tied to a drug's price across the retail prescription drug supply chain in part D, covering their type, size and prevalence among managers, plans, wholesalers, pharmacies, manufacturers, brokers and others, business models, differences between affiliated and unaffiliated firms, potential conflicts of interest, changes over time and across market segments, and the effects on federal health programs and beneficiaries. The report is due to Congress within two years of enactment.
What the document actually says“Not later than 2 years after the date of enactment of this section, the Comptroller General shall submit to Congress a report containing the results of the study conducted under paragraph (1), together with recommendations for such legislation and administrative action as the Comptroller General determines appropriate.”
Within two years a watchdog office must send Congress a report on the study. It must add what it thinks Congress or the agency should do.
Fees set as a share of a drug's price run through the whole chain. The study maps where they are and what they do.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.